scholarly journals Oesophageal squamous cell neoplasia in head and neck cancer patients: upregulation of COX-2 during carcinogenesis

2003 ◽  
Vol 88 (8) ◽  
pp. 1217-1222 ◽  
Author(s):  
K Maaser ◽  
P Däubler ◽  
B Barthel ◽  
B Heine ◽  
B von Lampe ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Squamous Cell ◽  
Cox 2

Osteoprotegerin and Bone Mass in Squamous Cell Head and Neck Cancer Patients

2006 ◽  
Vol 78 (6) ◽  
pp. 343-347 ◽  
Author(s):  
C. Valero ◽  
J. M. Olmos ◽  
F. Rivera ◽  
J. L. Hernández ◽  
M. E. Vega ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Bone Mass ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Squamous Cell

Distant metastases in terminal head and neck cancer patients

1997 ◽  
Vol 111 (5) ◽  
pp. 454-458 ◽  
Author(s):  
Yoav P. Talmi ◽  
Daniel Cotlear ◽  
Alexander Waller ◽  
Zeev Horowitz ◽  
Abraham Adunski ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Primary Tumour ◽  
Cell Cancer ◽  
Distant Metastases ◽  
Clinical Series

AbstractWith improved control of cancer above the clavicles, distant metastases (DM) are frequently more seen and are becoming a more common cause of morbidity and mortality. The present study defined the incidence of distant metastases in a cohort of terminal head and neck cancer patients (HNCP) and compared it to current reported data. The incidence of distant metastases in relation to the primary tumour was evaluated and their impact on survival was assessed. A retrospective survey of patient charts was made, based on the hospice database and original referring hospital charts. Data of 59 patients admitted to the hospice were evaluated. The incidence and location of locoregional and distant disease were studied and effects on survival analyzed.The overall survival from diagnosis to demise was 42.7 months. Thyroid cancer was seen in 20.3 per cent of cases and squamous cell cancer was seen in 59.3 per cent. Distant metastases were found in 83 per cent and 48.6 per cent of patients respectively. Laryngeal cancer patients had a 54.5 per cent incidence of distant metastases. Locoregional disease was seen in 47 per cent of cases and 35.7 per cent of them had distant metastases while a 64.3 per cent incidence of distant metastases was found in cases without locoregional disease. Mean survival was 47.3 months with distant metastases vs 36.5 months without metastases. The difference was not statistically significant.The incidence of distant metastases in squamous cell cancer in terminalHNCP was 48.6 per cent. This is the highest reported incidence of metastases in a clinical series. Patients without locoregional disease had almost a two-fold incidence of metastases. Survival was not affected by metastases in this series.

scholarly journals Progress of molecular targeted therapy for head and neck cancer in clinical aspects

2021 ◽  
Vol 2 (1) ◽  
Author(s):  
Kenji Nakano
Keyword(s):  
Squamous Cell Carcinoma ◽  
Clinical Trials ◽  
Head And Neck Cancer ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Squamous Cell ◽  
Molecular Targeted Therapy

AbstractSince the body’s head and neck area affects many functions such as breathing, swallowing, and speaking, systemic treatments to head and neck cancer patients are important not only for survival but also for preserving functions and quality of life. With the progress that has been made in molecular targeted therapy, anti-EGFR antibody (cetuximab) and immune checkpoint inhibitors (nivolumab, pembrolizumab) have provided survival benefits to head and neck cancer patients and are approved for clinical practice. Clinical trials incorporating these new drugs for patients with locally advanced head/neck cancers are underway. However, the existing clinical evidence regarding molecular targeted drugs for head and neck cancers is based mostly on clinical trials allocated to squamous cell carcinoma patients. New targeted therapies for non-squamous cell carcinoma patients were recently reported, e.g., tyrosine kinase inhibitors for the treatment of thyroid cancers and HER2-targeted therapy for salivary gland cancers. With the goal of improving local control, molecular targeted treatment strategies as salvage local therapy are being investigated, including boron neutron capture therapy (BNCT) and near-infrared photoimmunotherapy (NIR-PIT). Herein the history and landscape of molecular targeted therapy for head and neck cancers are summarized and reviewed.

Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition

2007 ◽  
Vol 56 (10) ◽  
pp. 1645-1652 ◽  
Author(s):  
Stephan Lang ◽  
Sanjay Tiwari ◽  
Michaela Andratschke ◽  
Iren Loehr ◽  
Lina Lauffer ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Immune Restoration ◽  
Cox 2

Squamous Cell Carcinoma Antigen and Protein-Bound Sialic Acid in the Management of Head and Neck Cancer

1991 ◽  
Vol 6 (4) ◽  
pp. 237-240 ◽  
Author(s):  
J.M. Bhatavdekar ◽  
D.D. Patel ◽  
H.H. Vora ◽  
D.B. Balar
Keyword(s):  
Squamous Cell Carcinoma ◽  
Head And Neck Cancer ◽  
Sialic Acid ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Squamous Cell ◽  
Response To Therapy ◽  
Squamous Cell Carcinoma Antigen

Serum squamous cell carcinoma antigen (SCCAg) and protein-bound sialic acid (PBSA) were measured in 43 head and neck cancer patients and 50 controls. SCCAg and PBSA were correlated with clinical stage, histological grade, presence/absence of keratin and disease course. Patients with advanced cancer (stage III and IV) and grade III tumors had higher PBSA levels but no such difference was observed for SCCAg. Head and neck cancer patients were grouped according to the disease status i.e. a) patients who developed recurrence and b) who responded to the adjuvant therapies. There was an excellent correlation between serial serum PBSA changes and the progression of disease or the response to therapy in patients with advanced head and neck cancer.

Sign in / Sign up

Export Citation Format

Share Document